TABLE 2.

Clinical variables and progression-free survival (univariate analyses)

	Progression-Free Survival
Variables	HR	95% CI	P	Reference
Pretreatment CA125 level continuous	1.00	1.00–1.00	0.128	Continuous
Posttreatment CA125 level continuous	1.00	1.00–1.00	0.009	Continuous
Posttreatment CA125 level
Positive	2.69	1.82–3.99	<0.001	Negative
Unknown	1.23	0.86–1.75	0.251
Age	1.01	0.99–1.02	0.243	Continuous
Ethnic Group – not white	0.87	0.62–1.23	0.436	White
Disease site	0.93	0.68–1.28	0.667	Ovary
Histology group
Papillary serous	0.75	0.51–1.10	0.14	Serous
Mixed	0.75	0.53–1.06	0.102
Other	0.59	0.38–0.92	0.019
FIGO stage
III	2.21	1.12–4.35	0.022	≤II
IV	4.83	2.41–9.68	<0.001
Unknown	2.72	1.05–7.06	0.04
Residual disease
<2 cm	1.60	1.14–2.25	0.006	No residual
>2 cm	2.64	1.79–3.9	<0.001
Unknown	1.89	1.14–3.13	0.013
Optimal debulking (operation note)
Yes	0.57	0.41–0.78	<0.001	No
Unknown	0.60	0.24–1.5	0.272
Neoadjuvant chemotherapy
No	0.56	0.43–0.74	<0.001	Yes
Unknown	1.02	0.32–3.24	0.968
Status postchemotherapy
Disease present	2.42	1.79–3.26	<0.001	No evidence of disease
Unknown	1.52	0.99–2.34	0.056